secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001477932-24-001695
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab removes eight directors, appoints four new directors and new CEO
--------------------------------------------------------------------------------

- Stockholders owning 50.1% (17,792,663 shares) approved removal of eight directors and appointment of four new directors via written consent.
- Eight prior directors removed: Yeat Min Fong, Chi Yuen Leong, Yee Meng Wong, Teng Fook Fong, Chee Keong Yap, Chak Hua Yew, Boon Teong Teoh, and Chai Ping Lin.
- New directors: Koon Wai Wong, Wei Foong Lim, Muhammad Azrul bin Abdul Hamid, and Chee Keong Yap (independent); terms expire at 2024 annual meeting.
- Su-Leng Tan Lee appointed CEO and Secretary effective Dec 11, 2023; two-year employment agreement with non-compete for 24 months after termination.
- Board committees reconstituted: Audit (Chair: Chee Keong Yap), Compensation (Chair: Muhammad Azrul bin Abdul Hamid), Nomination & Corp Gov (Chair: Muhammad Azrul bin Abdul Hamid).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224001695/0001477932-24-001695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224001695/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-001695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer